fbpx

Excerpts from the publication

Methods: To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. We assessed changes in depression severity with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating scale at baseline, and at 1 (D1), 2 (D2), and 7 (D7) days after dosing.

Results: We observed significant antidepressant effects of ayahuasca when compared with placebo at all-time points. MADRS scores were significantly lower in the ayahuasca group compared with placebo at D1 and D2 (p = 0.04), and at D7 (p < 0.0001). Between-group effect sizes increased from D1 to D7 (D1: Cohen's d = 0.84; D2: Cohen's d = 0.84; D7: Cohen's d = 1.49). Response rates were high for both groups at D1 and D2, and significantly higher in the ayahuasca group at D7 (64% v. 27%; p = 0.04). Remission rate showed a trend toward significance at D7 (36% v. 7%, p = 0.054).

Conclusions: To our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression.

Read more

Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review

Jason Ng, Joshua D Rosenblat, Leanna M W Lui, Kayla M Teopiz, Yena Lee, Orly Lipsitz, Rodrigo B Mansur, Nelson B Rodrigues, Flora Nasri, Hartej Gill, Danielle S Cha, Mehala Subramaniapillai, Roger C Ho , Bing Cao, Roger S McIntyre
October 2021

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Elliot Marseille , James G. Kahn, Berra Yazar-Klosinski, Rick Doblin
October 2020

Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression

Eric P McMullen, Yena Lee, Orly Lipsitz, Leanna M W Lui, Maj Vinberg, Roger Ho, Nelson B Rodrigues, Joshua D Rosenblat, Bing Cao, Hartej Gill, Kayla M Teopiz, Danielle S Cha, Roger S McIntyre
April 2021

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Rafael Guimarães dos Santos, José Carlos Bouso, Juliana Mendes Rocha, Giordano Novak Rossi, Jaime E Hallak
March 2021